The role of ixekizumab in non-radiographic axial spondyloarthritis

Koo, Bon San; Kim, So Yeon

doi:10.1177/1759720x20986734

Cited by 5 publications

(6 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Secukinumabmentioning

confidence: 99%

“… 28 In 2020, secukinumab was approved for the treatment of adults with nr-axSpA with objective signs of inflammation who have responded inadequately to NSAIDs. 24 In the European Union (EU), the recommended dose of secukinumab for patients with axSpA is 150 mg by subcutaneous injection, with loading doses administered at weeks 0, 1, 2, 3 and 4, followed by subsequent doses administered every 4 weeks. 27 In contrast, in the United States (US), secukinumab 150 mg can be administered with or without the loading dose.…”

Section: Secukinumabmentioning

confidence: 99%

“…23 At present, there are two anti-IL-17A biologics approved for the treatment of axSpA: secukinumab and ixekizumab. 24 Further anti-IL-17 biologics, such as brodalumab and bimekizumab, are being evaluated in clinical trials in patients with axSpA; these therapies, however, are still in clinical development and are not currently indicated in this patient population. 25,26 Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor, reducing IL-17A-mediated contributions to inflammatory diseases.…”

Section: Secukinumabmentioning

confidence: 99%

“…Because secukinumab gained approval in the EU and US (in 2016 for r-axSpA and in 2020 for nr-axSpA), multiple registries and studies have collected RWE for secukinumab. 24,76 Here, we will focus on two key registries [EuroSpA and Consortium of Rheumatology Researchers of North America (CORRONA)] and studies (AQUILA and SERENA). [77][78][79][80] EuroSpA is a collaboration between 16 European SpA registries.…”

Section: Real-world Evidence (Rwe)mentioning

confidence: 99%

See 3 more Smart Citations

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence

Braun

Kiltz

Bühring

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by inflammation and new bone formation in the axial skeleton. AxSpA is considered a spectrum of disease that includes two subtypes identified by the Assessment in SpondyloArthritis International Society classification criteria, namely, radiographic (r-axSpA usually referred to as ankylosing spondylitis) and non-radiographic axSpA (nr-axSpA). Although the burden of disease appears similar between the two classified subtypes, the degree of inflammation, as assessed by magnetic resonance imaging and C-reactive protein, and the degree of new bone formation are significantly higher in r-axSpA than in nr-axSpA. Nevertheless, axSpA is considered one disease with different courses. International guidelines for the management of axSpA have outlined treatment goals focused on control of signs and symptoms, inflammation, prevention of progressive structural damage, preservation of physical function, normalization of social participation and improvement of quality of life. The pathogenesis of axSpA has not been completely elucidated to date. A strong link between human leukocyte antigen B27 and axSpA, however, has been identified, and the success of anti-tumour necrosis factor and anti-interleukin (IL)-17A therapy has highlighted some of the key pro-inflammatory cytokines involved. The anti-IL-17A monoclonal antibody secukinumab is approved for the treatment of ankylosing spondylitis and nr-axSpA in the European Union and United States. In this narrative review, we discuss data for secukinumab in axSpA from randomized controlled trials, including MEASURE trials in AS and PREVENT in nr-axSpA, and real-world evidence.

show abstract

Section: Secukinumabmentioning

confidence: 99%

Section: Secukinumabmentioning

confidence: 99%

Section: Secukinumabmentioning

confidence: 99%

Section: Real-world Evidence (Rwe)mentioning

confidence: 99%

See 2 more Smart Citations

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence

Braun

Kiltz

Bühring

et al. 2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…Sex differences in clinical presentation may also affect a clinician’s perception of disease severity and activity, and thus influence disease management [ 16 ]. Cytokine signalling through the interleukin-17 (IL-17) pathway is a key contributor to the pathogenesis of axSpA, and IL-17A inhibitors are an efficacious alternative to tumour necrosis factor inhibitor (TNFi) for patients with axSpA [ 17 , 18 ]. IL-17 signature studies have shown upregulated Il-17 gene expression in male patients compared to female patients [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials

et al. 2022

View full text Add to dashboard Cite

Objectives Assess baseline characteristics and treatment response to ixekizumab (IXE) categorised by sex in patients with radiographic axial spondyloarthritis (r-axSpA) and non-radiographic axSpA (nr-axSpA) up to 52 weeks. Methods Data were analysed from three randomised controlled trials of IXE through 52 weeks. Patients fulfilled ASAS classification criteria for r-axSpA or nr-axSpA and were randomised to receive 80 mg subcutaneous administration of IXE every 2 weeks (Q2W) or 4 weeks (Q4W), or placebo (16 weeks COAST-V/W; 52 weeks COAST-X). Baseline characteristics and treatment outcomes were assessed. Patients were categorised by sex; methods included non-responder imputation for categorical variables, and modified baseline observation carried forward for continuous efficacy variables. Results At presentation, female patients had higher disease burden as reflected by significantly higher spinal pain at night, fatigue scores and pain/swelling in joints other than the neck, back or hip. ASAS40 response rate with the approved label dose, IXEQ4W, was achieved in 39% of male patients with r-axSpA by week 16, and 44% by week 52. For female patients, 16.7% and 33.3% achieved ASAS40 at week 16 and 52, respectively. In nr-axSpA, 46% of male patients achieved ASAS40 at week 16 and 30% at week 52. In total, 23.9% of female patients achieved ASAS40 at week 16, and 30.4% at week 52. Conclusions This analysis demonstrates that for the axSpA disease spectrum, female patients present with higher disease burden. Following treatment with IXE, there is a higher proportion of male responders up to 16 weeks, while female patients show less robust responses for the first 16 weeks but larger responses from weeks 16 through 52. Trial Registration Numbers NCT02696785, NCT02696798 and NCT02757352. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02132-2.

show abstract

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis

Atzeni

Carriero

Boccassini

et al. 2021

ITT

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) describes a group of chronic inflammatory rheumatic diseases primarily involving the axial skeleton. IL-17 is involved in the pathogenesis of numerous inflammatory diseases, including inflammatory arthritis. Until a few years ago, the only biological agents licensed for the treatment of axSpA and nr-axSpA were TNF inhibitors. However, as some patients did not respond to TNF inhibition or experienced secondary failure, the introduction of the first two IL-17 inhibitors (secukinumab [SEC] and ixekizumab [IXE]) has extended the treatment options, and there are now three others (bimekizumab, brodalumab and netakimab) in various stages of clinical development. The last ten years have seen the development of a number of therapeutic recommendations that aimed at improving the management of axSpA patients. The aim of this narrative review of the published literature concerning the role of IL-17 in the pathogenesis of SpA, and the role of IL-17 inhibitors in the treatment of axSpA, is to provide a comprehensive picture of the clinical efficacy and safety of the drugs themselves, and the treatment strategies recommended in the international guidelines.

show abstract

The role of ixekizumab in non-radiographic axial spondyloarthritis

Cited by 5 publications

References 87 publications

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis

Contact Info

Product

Resources

About